Nairobi, April 3 (Xinhua) -- A candidate Ebola vaccine has demonstrated a high degree of efficacy, safety and could deal a final blow to the hemorrhagic fever that has killed some 10,000 people in West Africa.
Results from the phase one trial of the Ebola vaccine rVSV ZEBOV released by Kenya's Medical Research Institute (KEMRI) on Thursday revealed its capacity to protect humans from the killer disease.
